Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia
- 30 July 2015
- journal article
- research article
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 373 (5), 438-447
- https://doi.org/10.1056/nejmoa1400283
Abstract
Apolipoprotein C-III (APOC3) is a key regulator of plasma triglyceride levels. Elevated triglyceride levels are associated with a risk of adverse cardiovascular events and pancreatitis. ISIS 304801 is a second-generation antisense inhibitor of APOC3 synthesis.Keywords
This publication has 45 references indexed in Scilit:
- Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and HumansCirculation Research, 2013
- Low-Density Lipoproteins Containing Apolipoprotein C-III and the Risk of Coronary Heart DiseaseCirculation, 2011
- Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for managementEuropean Heart Journal, 2011
- Impact of Combined Deficiency of Hepatic Lipase and Endothelial Lipase on the Metabolism of Both High-Density Lipoproteins and Apolipoprotein B–Containing LipoproteinsCirculation Research, 2010
- Apolipoprotein C-III and the Metabolic Basis for Hypertriglyceridemia and the Dense Low-Density Lipoprotein PhenotypeCirculation, 2010
- Metabolism of Very-Low-Density Lipoprotein and Low-Density Lipoprotein Containing Apolipoprotein C-III and Not Other Small ApolipoproteinsArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent CardioprotectionScience, 2008
- Prevention of Recurrent Acute Pancreatitis in Patients with Severe HypertriglyceridemiaPancreas, 1996
- Modulation of Lipoprotein B Binding to the LDL Receptor by Exogenous Lipids and Apolipoproteins CI, CII, CIII, and EArteriosclerosis, Thrombosis, and Vascular Biology, 1995
- Apolipoprotein B metabolism in subjects with deficiency of apolipoproteins CIII and AI. Evidence that apolipoprotein CIII inhibits catabolism of triglyceride-rich lipoproteins by lipoprotein lipase in vivo.JCI Insight, 1986